At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 163 enrolled
Drug / intervention
Chondroitin 4&6 sulfate (Condrosulf) +1 moredrug
Likely dose
Chondroitin 4&6 sulfate (Condrosulf) 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study
In Brief
A Phase 3 clinical trial evaluating Chondroitin 4&6 sulfate (Condrosulf) and Placebo for Osteoarthrosis. Completed, enrolled 163 participants.
Detailed Summary
The goal of the present study is to investigate the effectiveness of Condrosulf® 800 mg tablets vs. placebo once a day for 6 months in the symptomatic treatment of finger joint osteoarthritis. Primary endpoints of the study are the evaluation of global spontaneous pain (Huskisson's Visual Analogue Scale: VAS) and the score of Dreiser's algo-functional index (FIHOA) during the treatment with the tested product, Condrosulf®, versus placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthrosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2005
First PostedFeb 2006
Primary CompletionDec 2009
Study CompletionAug 2010
TodayJul 2026
First PostedFeb 14, 2006
Enrollment StartJun 1, 2005
Primary CompletionDec 1, 2009
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 20.4 years ago
Interventions
Chondroitin 4&6 sulfate (Condrosulf)drug
800 mg/day for 6 months
Placeboother
800 mg placebo/day for 6 months